MA46608A - Formulation liposomale destinée à être utilisée dans le traitement du cancer - Google Patents

Formulation liposomale destinée à être utilisée dans le traitement du cancer

Info

Publication number: MA46608A
Authority: MA; Morocco
Prior art keywords: cancer; treatment; liposomal formulation; liposomal; formulation
Prior art date: 2016-10-28

Application number

MA046608A

Other languages

English (en)

Other versions

MA46608B1 (fr

Inventor

Marco Paolo De

Marina Gurina

Malika Larabi

Christiane Schiedel

Henricus Tiemessen

Peter Wessels

Original Assignee

Servier Lab

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-28

Filing date

2017-10-27

Publication date

2019-09-04

2017-10-27 Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab

2019-09-04 Publication of MA46608A publication Critical patent/MA46608A/fr

2022-08-31 Publication of MA46608B1 publication Critical patent/MA46608B1/fr

Links

206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA46608A 2016-10-28 2017-10-27 Formulation liposomale utile pour le traitement du cancer MA46608B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16306415		2016-10-28
PCT/EP2017/077538 WO2018078064A1 (fr)	2016-10-28	2017-10-27	Formulation liposomale destinée à être utilisée dans le traitement du cancer

Publications (2)

Publication Number	Publication Date
MA46608A true MA46608A (fr)	2019-09-04
MA46608B1 MA46608B1 (fr)	2022-08-31

Family

ID=57288337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA46608A MA46608B1 (fr)	2016-10-28	2017-10-27	Formulation liposomale utile pour le traitement du cancer

Country Status (36)

Country	Link
US (1)	US10722466B2 (fr)
EP (1)	EP3532067B1 (fr)
JP (1)	JP7041676B2 (fr)
KR (1)	KR102653436B1 (fr)
CN (1)	CN109922808B (fr)
AR (1)	AR109981A1 (fr)
AU (1)	AU2017350499B2 (fr)
BR (1)	BR112019008263A2 (fr)
CA (1)	CA3041592C (fr)
CO (1)	CO2019004190A2 (fr)
CU (1)	CU20190046A7 (fr)
CY (1)	CY1125446T1 (fr)
DK (1)	DK3532067T3 (fr)
EA (1)	EA201991025A1 (fr)
ES (1)	ES2923929T3 (fr)
GE (1)	GEP20217244B (fr)
HR (1)	HRP20220952T1 (fr)
HU (1)	HUE059448T2 (fr)
IL (1)	IL266198B2 (fr)
LT (1)	LT3532067T (fr)
MA (1)	MA46608B1 (fr)
MD (1)	MD3532067T2 (fr)
MX (1)	MX391096B (fr)
MY (1)	MY194730A (fr)
PH (1)	PH12019500804A1 (fr)
PL (1)	PL3532067T3 (fr)
PT (1)	PT3532067T (fr)
RS (1)	RS63400B1 (fr)
RU (1)	RU2756755C2 (fr)
SG (1)	SG11201903326RA (fr)
SI (1)	SI3532067T1 (fr)
TN (1)	TN2019000117A1 (fr)
TW (1)	TWI749091B (fr)
UA (1)	UA126910C2 (fr)
UY (1)	UY37459A (fr)
WO (1)	WO2018078064A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200041942A (ko)	2017-08-15	2020-04-22	애브비 인코포레이티드	거대환식 mcl-1 저해제 및 이의 용도
CN110964034B (zh) *	2018-09-29	2022-04-12	江苏恒瑞医药股份有限公司	嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) *	2018-10-15	2021-05-26	Servier Lab	Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh)	2018-11-14	2024-07-21	法商施維雅藥廠	Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
TW202114682A (zh)	2019-06-17	2021-04-16	法商施維雅藥廠	Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
WO2022090443A1 (fr)	2020-10-30	2022-05-05	Les Laboratoires Servier	Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1
WO2022212863A1 (fr)	2021-04-01	2022-10-06	Vestaron Corporation	Formulations de liposomes destinées à l'administration de pesticides et leurs procédés de production et d'utilisation
CA3222752A1 (fr)	2021-06-11	2022-12-15	Gilead Sciences, Inc.	Inhibiteurs de mcl-1 en combinaison avec des conjugues anti-corps-medicament
EP4351564A1 (fr)	2021-06-11	2024-04-17	Gilead Sciences, Inc.	Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS607932A (ja) *	1983-06-29	1985-01-16	Dai Ichi Seiyaku Co Ltd	リポソーム懸濁液およびその製法
GB8613811D0 (en)	1986-06-06	1986-07-09	Phares Pharm Res Nv	Composition & method
US5580899A (en) *	1995-01-09	1996-12-03	The Liposome Company, Inc.	Hydrophobic taxane derivatives
GB9601120D0 (en)	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
EP1013268A1 (fr) *	1998-06-30	2000-06-28	Rohto Pharmaceutical Co., Ltd.	Compositions contenant des liposomes et/ou des emulsions et leur procede de preparation
HUP0202669A3 (en) *	1999-09-09	2004-06-28	Univ California	Cationic liposome delivery of taxanes to angiogenic bloos vessels
KR20010100194A (ko) *	2000-03-13	2001-11-14	박호군	여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
JP2002080400A (ja) *	2000-06-23	2002-03-19	Takeda Chem Ind Ltd	リン脂質含有薬物の製造法
CN1116875C (zh) *	2000-10-19	2003-08-06	南京振中生物工程有限公司	紫杉醇脂质组合物及其制备方法
ES2332584T3 (es)	2001-03-27	2010-02-09	Phares Pharmaceutical Research N.V.	Metodo y composicion para solubilizar un compuesto biologicamente activo con baja solubilidad en agua.
US7666876B2 (en) *	2002-03-19	2010-02-23	Vernalis (R&D) Limited	Buprenorphine formulations for intranasal delivery
KR20050105451A (ko) *	2003-02-03	2005-11-04	네오팜 인코포레이티드	안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제
JP2005075783A (ja) *	2003-09-01	2005-03-24	Otsuka Pharmaceut Factory Inc	難溶性化合物の可溶化または分散化用組成物
JP2005225818A (ja) *	2004-02-13	2005-08-25	Otsuka Pharmaceut Factory Inc	パクリタキセル又はドセタキセルの医薬組成物
CA2681302C (fr)	2007-03-19	2013-07-23	Dhiraj Khattar	Compositions proliposomales et liposimale de composes faiblement hydrosolubles
PL2344198T3 (pl)	2008-09-27	2021-05-31	Jina Pharmaceuticals Inc.	Preparaty farmaceutyczne na bazie lipidów do stosowania miejscowego
RU2476216C1 (ru) *	2009-03-30	2013-02-27	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Липосомальная композиция
SI2508170T1 (sl) *	2009-12-03	2015-12-31	Jiangsu Hengrui Medicine Co., Ltd.	Liposom z irinotekanom ali njegovim hidrokloridom in njun postopek priprave
JP2012051823A (ja) *	2010-08-31	2012-03-15	Fujifilm Corp	難容性薬物含有水中油型乳化組成物及びその製造方法
CN101926757B (zh) *	2010-09-01	2013-01-02	北京大学	一种难溶性药物的液体组合物及其制备方法
RU2013129777A (ru) *	2010-12-08	2015-01-20	Ф. Хоффманн-Ля Рош Аг	Липосомальный препарат далцетрапиба
JP2014506922A (ja) *	2011-03-01	2014-03-20	ティーオー − ビービービーホールディングベスローテンフェンノートシャップ	難水溶性物質の高度なアクティブリポソームローディング
CN103622911B (zh)	2013-11-19	2015-12-30	常州金远药业制造有限公司	一种难溶性药物脂质体制备方法
FR3015483B1 (fr) *	2013-12-23	2016-01-01	Servier Lab	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2017
- 2017-10-27 UY UY0001037459A patent/UY37459A/es not_active Application Discontinuation
- 2017-10-27 RU RU2019115688A patent/RU2756755C2/ru active
- 2017-10-27 CU CU2019000046A patent/CU20190046A7/es unknown
- 2017-10-27 US US16/344,431 patent/US10722466B2/en active Active
- 2017-10-27 JP JP2019522453A patent/JP7041676B2/ja not_active Expired - Fee Related
- 2017-10-27 WO PCT/EP2017/077538 patent/WO2018078064A1/fr not_active Ceased
- 2017-10-27 HR HRP20220952TT patent/HRP20220952T1/hr unknown
- 2017-10-27 MX MX2019004941A patent/MX391096B/es unknown
- 2017-10-27 BR BR112019008263A patent/BR112019008263A2/pt not_active Application Discontinuation
- 2017-10-27 SG SG11201903326RA patent/SG11201903326RA/en unknown
- 2017-10-27 MY MYPI2019002297A patent/MY194730A/en unknown
- 2017-10-27 SI SI201731200T patent/SI3532067T1/sl unknown
- 2017-10-27 AU AU2017350499A patent/AU2017350499B2/en not_active Ceased
- 2017-10-27 PT PT177879392T patent/PT3532067T/pt unknown
- 2017-10-27 AR ARP170102984A patent/AR109981A1/es not_active Application Discontinuation
- 2017-10-27 ES ES17787939T patent/ES2923929T3/es active Active
- 2017-10-27 EP EP17787939.2A patent/EP3532067B1/fr active Active
- 2017-10-27 TN TNP/2019/000117A patent/TN2019000117A1/en unknown
- 2017-10-27 HU HUE17787939A patent/HUE059448T2/hu unknown
- 2017-10-27 LT LTEPPCT/EP2017/077538T patent/LT3532067T/lt unknown
- 2017-10-27 GE GEAP201715047A patent/GEP20217244B/en unknown
- 2017-10-27 DK DK17787939.2T patent/DK3532067T3/da active
- 2017-10-27 MA MA46608A patent/MA46608B1/fr unknown
- 2017-10-27 KR KR1020197015033A patent/KR102653436B1/ko active Active
- 2017-10-27 TW TW106137030A patent/TWI749091B/zh not_active IP Right Cessation
- 2017-10-27 UA UAA201905614A patent/UA126910C2/uk unknown
- 2017-10-27 MD MDE20190973T patent/MD3532067T2/ro unknown
- 2017-10-27 CN CN201780067045.2A patent/CN109922808B/zh not_active Expired - Fee Related
- 2017-10-27 EA EA201991025A patent/EA201991025A1/ru unknown
- 2017-10-27 CA CA3041592A patent/CA3041592C/fr active Active
- 2017-10-27 PL PL17787939.2T patent/PL3532067T3/pl unknown
- 2017-10-27 RS RS20220677A patent/RS63400B1/sr unknown
- 2017-10-27 IL IL266198A patent/IL266198B2/en unknown
2019
- 2019-04-12 PH PH12019500804A patent/PH12019500804A1/en unknown
- 2019-04-26 CO CONC2019/0004190A patent/CO2019004190A2/es unknown
2022
- 2022-08-02 CY CY20221100526T patent/CY1125446T1/el unknown

Also Published As

Publication number	Publication date
SI3532067T1 (sl)	2022-09-30
AU2017350499B2 (en)	2023-08-10
EP3532067B1 (fr)	2022-05-04
WO2018078064A1 (fr)	2018-05-03
MX391096B (es)	2025-03-21
CN109922808A (zh)	2019-06-21
MX2019004941A (es)	2019-06-24
EP3532067A1 (fr)	2019-09-04
BR112019008263A2 (pt)	2019-07-09
IL266198A (en)	2019-06-30
HUE059448T2 (hu)	2022-11-28
PH12019500804A1 (en)	2020-01-20
MY194730A (en)	2022-12-15
IL266198B2 (en)	2023-11-01
TW201818942A (zh)	2018-06-01
CA3041592C (fr)	2023-01-17
CA3041592A1 (fr)	2018-05-03
TWI749091B (zh)	2021-12-11
DK3532067T3 (da)	2022-07-25
TN2019000117A1 (en)	2020-10-05
JP7041676B2 (ja)	2022-03-24
US20200054557A1 (en)	2020-02-20
GEP20217244B (en)	2021-04-26
UY37459A (es)	2018-05-31
AR109981A1 (es)	2019-02-13
US10722466B2 (en)	2020-07-28
PL3532067T3 (pl)	2022-08-16
RU2756755C2 (ru)	2021-10-05
SG11201903326RA (en)	2019-05-30
MA46608B1 (fr)	2022-08-31
RU2019115688A (ru)	2020-11-30
MD3532067T2 (ro)	2022-10-31
ES2923929T3 (es)	2022-10-03
EA201991025A1 (ru)	2019-11-29
RU2019115688A3 (fr)	2021-01-13
CU20190046A7 (es)	2019-12-03
PT3532067T (pt)	2022-07-04
CN109922808B (zh)	2023-02-03
CY1125446T1 (el)	2025-05-09
CO2019004190A2 (es)	2019-07-10
IL266198B1 (en)	2023-07-01
KR102653436B1 (ko)	2024-03-29
LT3532067T (lt)	2022-08-25
HRP20220952T1 (hr)	2022-10-28
JP2019532973A (ja)	2019-11-14
AU2017350499A1 (en)	2019-05-09
RS63400B1 (sr)	2022-08-31
KR20190076004A (ko)	2019-07-01
UA126910C2 (uk)	2023-02-22

Publication	Publication Date	Title
MA46608A (fr)	2019-09-04	Formulation liposomale destinée à être utilisée dans le traitement du cancer
EP3631846A4 (fr)	2021-03-10	Mandrin électrostatique destiné à être utilisé dans le traitement de semi-conducteur
HUE054548T2 (hu)	2021-09-28	Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3431105A4 (fr)	2019-04-03	Composition médicinale pour le traitement du cancer
EP3436002A4 (fr)	2019-12-04	Combinaisons pharmaceutiques pour le traitement du cancer
EP3431102A4 (fr)	2019-09-25	Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer
PL4272834T3 (pl)	2026-03-02	Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych
HUE053115T2 (hu)	2021-06-28	Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
EP3432927A4 (fr)	2019-11-20	Inhibiteurs trispécifiques pour le traitement du cancer
EP3474854A4 (fr)	2020-02-19	Associations médicamenteuses pour le traitement du cancer
PL3381451T3 (pl)	2025-11-12	Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
PL3503890T3 (pl)	2025-03-24	Stosowanie pridopidyny w leczeniu dystonii
MA47111A (fr)	2019-10-30	Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA51823A (fr)	2021-05-19	Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
MA45848A (fr)	2019-06-12	Cobicistat destiné à être utilisé dans des traitements du cancer
ME03351B (fr)	2019-10-20	Composé stéroïde destiné à être utilisé dans le traitement de l'encéphalopathie hépatique
EP3294338A4 (fr)	2019-07-17	Macropinocytose utilisée dans l'identification du cancer
EP3848022C0 (fr)	2023-06-07	Agent thérapeutique pour utilisation dans le traitement d'infections
MA45046A (fr)	2019-03-27	Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
MA51978A (fr)	2021-01-20	Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique
EP3813870C0 (fr)	2023-11-15	Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer
MA43861A (fr)	2021-05-05	Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie
IL264407A (en)	2019-02-28	Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
SI3733712T1 (sl)	2023-12-29	Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba
IT201600081379A1 (it)	2018-02-03	Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.